Medicenna Therapeutics Corp

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicennas long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicennas early-stage BiSKITsTM program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically cold tumors. Medicennas IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly...

Cytokines and oncology

Medicenna therapeutics corp operates in the Biotechnology research industry.

Medicenna therapeutics corp's revenue is 11m - 100m

Medicenna therapeutics corp has 11 - 50 employees.